Investigation Report on China Rivaroxaban Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||332303|
|出版日期||內容資訊||英文 20 Pages
|Rivaroxaban的中國市場 Investigation Report on China Rivaroxaban Market, 2010-2019|
|出版日期: 2015年06月04日||內容資訊: 英文 20 Pages||
Rivaroxaban，由Bayer及Johnson & Johnson所開發的第一個直接凝血因子Xa抑制劑。Rivaroxaban以Xarelto為商標名在2008年10月通過加拿大及歐洲、2011年7月通過FDA認証，目前已有100個以上國家核可認証。根據Bayer和Johnson & Johnson的統計，Rivaroxaban的全球市場銷售量在2013年達到21億2400萬美元。此外中國市場自2009年推出以來銷售量便迅速擴大，2010年寫下2000萬人民幣的銷售量記錄，到2014年更成長到1億4000萬人民幣。
Venous Thrombus Embolism (VTE), the general term for deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a grave threat to those patients who have accepted Total Hip Replacement (THR) or Total Knee Replacement (TKR). It is estimated that blood clots form in 50% of THR patients and 60% of TKR patients.
According to some experts, rivaroxaban and dabigatran are the most promising antithrombotic agents which will add a new milestone to the development of cardiovascular drugs. Rivaroxaban is the first available orally active direct factor Xa inhibitor developed by Bayer/ Johnson & Johnson. In Oct. 2008, rivaroxaban was approved to come into the Canada and the EU markete under the trade name of Xarelto while on Jul. 1, 2011, it was approved by FDA to enter the American market. Rivaroxaban has been approved by more than 100 countries in the world and succeeded in entering over 75 countries. According to the statistics of Bayer/ Johnson & Johnson, the sales value of rivaroxaban in the world exceeded USD 2.124 billion in 2013, increasing by 219% compared with last year.
After rivaroxaban entering the Chinese market under the trade name of Xarelto in the latter half of 2009, it develops fast with annual sales rising from less than CNY 20 million in 2010 to CNY 140 million in 2014 and CAGR reaching up to over 70% during the period of 2010-2014. Currently, the rivaroxaban market in China has been monopolized by Bayer. The price of rivaroxaban is relatively high for it is imported. The price range of 10 mg rivaroxaban (tablets, 5 tab. per package) is 364.20-388.68 CNY/package in sample hospitals with cities differing slightly in its price. Some Chinese enterprises have been developing the generic drugs of rivaroxaban. And it is estimated that the market size of rivaroxaban in China will keep expanding in the next few years.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: